These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 9692220)
41. A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer. Chen M; Song F; Liu Y; Tian J; Liu C; Li R; Zhang Q Nanoscale; 2019 Mar; 11(9):3814-3826. PubMed ID: 30600823 [TBL] [Abstract][Full Text] [Related]
42. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842 [TBL] [Abstract][Full Text] [Related]
43. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Tainton KM; Smyth MJ; Jackson JT; Tanner JE; Cerruti L; Jane SM; Darcy PK; Johnstone RW Cell Death Differ; 2004 Sep; 11(9):1028-37. PubMed ID: 15131592 [TBL] [Abstract][Full Text] [Related]
44. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes]. Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453 [TBL] [Abstract][Full Text] [Related]
45. Function of P-glycoprotein expressed in placenta and mole. Nakamura Y; Ikeda S; Furukawa T; Sumizawa T; Tani A; Akiyama S; Nagata Y Biochem Biophys Res Commun; 1997 Jun; 235(3):849-53. PubMed ID: 9207250 [TBL] [Abstract][Full Text] [Related]
46. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099 [TBL] [Abstract][Full Text] [Related]
47. Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP). Slapak CA; Martell RL; Terashima M; Levy SB Biochem Pharmacol; 1996 Nov; 52(10):1569-76. PubMed ID: 8937472 [TBL] [Abstract][Full Text] [Related]
48. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide. Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430 [TBL] [Abstract][Full Text] [Related]
49. A novel taxane active against an orthotopically growing human glioma xenograft. Laccabue D; Tortoreto M; Veneroni S; Perego P; Scanziani E; Zucchetti M; Zaffaroni M; D'Incalci M; Bombardelli E; Zunino F; Pratesi G Cancer; 2001 Dec; 92(12):3085-92. PubMed ID: 11753988 [TBL] [Abstract][Full Text] [Related]
50. New active paclitaxel glucuronide derivative with improved water solubility. Paradis R; Page M Int J Oncol; 1998 Feb; 12(2):391-4. PubMed ID: 9459663 [TBL] [Abstract][Full Text] [Related]
51. Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein to a cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine. Ferry D; Boer R; Callaghan R; Ulrich WR Int J Clin Pharmacol Ther; 2000 Mar; 38(3):130-40. PubMed ID: 10739116 [TBL] [Abstract][Full Text] [Related]
52. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396 [TBL] [Abstract][Full Text] [Related]
53. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells. Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333 [TBL] [Abstract][Full Text] [Related]
54. Both ATP sites of human P-glycoprotein are essential but not symmetric. Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234 [TBL] [Abstract][Full Text] [Related]
55. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Chiang CD; Song EJ; Yang VC; Chao CC Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401 [TBL] [Abstract][Full Text] [Related]
56. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4'-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells. Borrel MN; Pereira E; Fiallo M; Garnier-Suillerot A Eur J Biochem; 1994 Jul; 223(1):125-33. PubMed ID: 7518390 [TBL] [Abstract][Full Text] [Related]
57. [Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay]. Untch M; Sevin BU; Untch A; Konecny G; Nestle-Krämling C; Korell M; Hepp H Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():311-3. PubMed ID: 7906979 [No Abstract] [Full Text] [Related]
58. [Studies on structure modification and structure-activity relationship of new taxoids derived from sinenxan a]. Huang G; Guo J; Liang X Yao Xue Xue Bao; 1998 Aug; 33(8):576-86. PubMed ID: 12016896 [TBL] [Abstract][Full Text] [Related]
59. Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. Mo L; Pospichalova V; Huang Z; Murphy SK; Payne S; Wang F; Kennedy M; Cianciolo GJ; Bryja V; Pizzo SV; Bachelder RE PLoS One; 2015; 10(7):e0131579. PubMed ID: 26148191 [TBL] [Abstract][Full Text] [Related]
60. Aureobasidins as new inhibitors of P-glycoprotein in multidrug resistant tumor cells. Kurome T; Takesako K; Kato I J Antibiot (Tokyo); 1998 Mar; 51(3):353-8. PubMed ID: 9589072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]